These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 9452347)
41. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Jenner P Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581 [No Abstract] [Full Text] [Related]
42. Neurotoxicity and neuroprotection in Parkinson's disease. Lange KW; Youdim MB; Riederer P J Neural Transm Suppl; 1992; 38():27-44. PubMed ID: 1491247 [TBL] [Abstract][Full Text] [Related]
43. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease. Sternic N; Kacar A; Filipovic S; Svetel M; Kostic VS Clin Neuropharmacol; 1998; 21(2):93-6. PubMed ID: 9579294 [TBL] [Abstract][Full Text] [Related]
44. Pregnancy in Parkinson's disease: unique case report and review of the literature. Scott M; Chowdhury M Mov Disord; 2005 Aug; 20(8):1078-9. PubMed ID: 16001415 [No Abstract] [Full Text] [Related]
45. Retention rate of selegiline in early Parkinson's disease: a retrospective survey. Keränen T; Mattila T; Luukkaala T; Kuusisto H Int J Clin Pract; 2012 Oct; 66(10):1014. PubMed ID: 22994335 [No Abstract] [Full Text] [Related]
46. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease. Lew MF Expert Rev Neurother; 2005 Nov; 5(6):705-12. PubMed ID: 16274328 [TBL] [Abstract][Full Text] [Related]
49. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease. Jansen Steur EN; Ballering LA Adv Neurol; 1999; 80():505-8. PubMed ID: 10410764 [No Abstract] [Full Text] [Related]
50. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition. LeWitt PA Clin Neuropharmacol; 2007; 30(5):305-7. PubMed ID: 17909310 [No Abstract] [Full Text] [Related]
51. Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits. Uzun M; Alp R; Uzlu E; Alp S; Citil M; Topcu B; Erdogan HM Eur Rev Med Pharmacol Sci; 2009; 13(2):95-8. PubMed ID: 19499843 [TBL] [Abstract][Full Text] [Related]
52. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Guay DR Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539 [TBL] [Abstract][Full Text] [Related]
53. Neuroprotection by selegiline and other MAO inhibitors. Stern G J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613 [TBL] [Abstract][Full Text] [Related]
54. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Fernandez HH; Chen JJ Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750 [TBL] [Abstract][Full Text] [Related]
55. Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide. LeWitt PA; Segel SA; Mistura KL; Schork MA Clin Neuropharmacol; 1993 Aug; 16(4):332-7. PubMed ID: 8374913 [TBL] [Abstract][Full Text] [Related]
56. Clinical inquiries. What is the best initial treatment of Parkinson's disease? Schreck J; Kelsberg G; Rich J; Ward R J Fam Pract; 2003 Nov; 52(11):897-9. PubMed ID: 14599387 [No Abstract] [Full Text] [Related]
57. Parkinson's disease. Clarke C; Moore AP Clin Evid; 2003 Dec; (10):1582-98. PubMed ID: 15555162 [No Abstract] [Full Text] [Related]
58. [Parkinson's disease and pregnancy: case report and literature review]. Routiot T; Lurel S; Denis E; Barbarino-Monnier P J Gynecol Obstet Biol Reprod (Paris); 2000 Sep; 29(5):454-7. PubMed ID: 11011274 [TBL] [Abstract][Full Text] [Related]
59. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors. Bainbridge JL; Page RL; Ruscin JM Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444 [TBL] [Abstract][Full Text] [Related]